secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2025-11-26T23:59:59+00:00
Accession:  0001193125-25-298551
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio discontinues NUV-1511 DDC program; redirects $100-150M to pipeline
-------------------------------------------------------------------------------

- Discontinued NUV-1511 due to inconsistent efficacy across cohorts; DDC platform continues.
- Projected $100-150M in R&D/CMC costs through 2029 reallocated to other pipeline molecules.
- First patient enrolled in part 2 of G203 study of safusidenib for IDH1-mutant glioma.
- Continued investment in IBTROZI (taletrectinib) commercial launch and TRUST-IV adjuvant study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525298551/0001193125-25-298551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525298551/d82457d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-298551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer